Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Spring loaded

Biotech enjoyed a big bounce as investors charged into the market late last week in the belief that the Federal Reserve Board's continued tightening is finally keeping inflation fears in check. Indeed, the BioCentury 100 led the key indicators on the week with a 21 percent gain, inching out the NASDAQ Composite's 19 percent move. Blue chips also moved upward, with the S&P 500 adding 7 percent and the Dow Jones Industrials up 5 percent.

More importantly, last week's BioCentury 100 gain reversed a three-week slide that was capped by a 12 percent decline the previous week, which had led to fears of a long, arid summer. The BioCentury 100 now is up 24 percent year-to-date, but still is down 6 percent on the quarter.

Euro IPOs get away

Two European companies made it out the IPO gate. In Germany, drug discovery company GPC Biotech (NMarkt:GPC) raised E103 million ($96 million) through the sale of 4.3 million shares at E24, in the upper end of its target range, underwritten by CS First Boston; Robertson, Stephens; SG Cowen; and Sal. Oppenheim. The stock opened at E

31.5 on Wednesday and closed

Read the full 1882 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE